Argenica Therapeutics’ ARG-007 gets FDA orphan drug status in hypoxic ischaemic encephalopathy
Argenica Therapeutics Limited (ASX: AGN), a leading biotechnology company specializing in developing therapeutics for brain injuries and neurological conditions, has achieved a significant milestone. The U.S. Food and Drug Administration (FDA) has awarded Orphan Drug Designation (ODD) status to its pioneering product, ARG-007, targeting the treatment of Hypoxic Ischaemic Encephalopathy (HIE). FDA’s Support for Rare […]